Payment overview · 2025
General Payments
$35,034.80
59 reported records · 16 companies
Healthcare provider profile · identity verified
David Lawrence Greco, M.D.
Allopathic & Osteopathic Physicians|Surgery · WHITEVILLE, NC · NPI 1881698868
Verified facts
What the public records show
CMS Open Payments records show David Lawrence Greco, M.D. received $35,034.80 in general payments during 2025 across 59 reported records.
INTUITIVE SURGICAL, INC. accounted for 97.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $34,260.48 | 97.8% | 23 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $199.12 | 0.6% | 8 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $97.40 | 0.3% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$69.56 | 0.2% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.18 | 0.1% | 3 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $44.57 | 0.1% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $42.57 | 0.1% | 2 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $40.98 | 0.1% | 2 | 2025 |
| LifeNet Health | Unresolved — no canonical attribution shown | $39.03 | 0.1% | 2 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $38.89 | 0.1% | 3 | 2025 |
| CashFlow Solutions, LLC | Unresolved — no canonical attribution shown | $38.11 | 0.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.98 | 0.1% | 2 | 2025 |
| Reprise Biomedical, Inc. | Unresolved — no canonical attribution shown | $26.06 | 0.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.99 | 0.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $20.61 | 0.1% | 1 | 2025 |
| HARTMANN USA, INC. | Unresolved — no canonical attribution shown | $14.27 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $32,000.00 | 8 |
| Food and Beverage | $2,132.71 | 45 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $500.00 | 1 |
| Travel and Lodging | $402.09 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $34,260.48 | 23 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $199.12 | 8 | 2025 |
Source payment records
|
|||||
| STRAVIX Normalized: stravix |
Biological | Smith+Nephew, Inc. | $77.02 | 4 | 2025 |
Source payment records
|
|||||
| AZURE XT DR MRI SURESCAN Normalized: azure xt dr mri surescan |
Device | Medtronic, Inc. | $69.56 | 1 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $57.61 | 3 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $49.18 | 3 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $44.57 | 2 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $42.57 | 2 | 2025 |
Source payment records
|
|||||
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $40.98 | 2 | 2025 |
Source payment records
|
|||||
| Integra Dermal Regeneration Template Normalized: integra dermal regeneration template |
Device | Integra LifeSciences Corporation | $40.98 | 2 | 2025 |
Source payment records
|
|||||
| PRIMATRIX Normalized: primatrix |
Device | Integra LifeSciences Corporation | $40.98 | 2 | 2025 |
Source payment records
|
|||||
| TheraGenesis Wound Matrix Normalized: theragenesis wound matrix |
Device | LifeNet Health | $39.03 | 2 | 2025 |
Source payment records
|
|||||
| LYMPHA PRESS OPTIMAL PLUS(US) BT Normalized: lympha press optimal plus us bt |
Device | CashFlow Solutions, LLC | $38.11 | 2 | 2025 |
Source payment records
|
|||||
| PCD-51 731A (US) - White Normalized: pcd 51 731a us white |
Device | CashFlow Solutions, LLC | $38.11 | 2 | 2025 |
Source payment records
|
|||||
| PCD-52 737A (US) White Normalized: pcd 52 737a us white |
Device | CashFlow Solutions, LLC | $38.11 | 2 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $32.98 | 2 | 2025 |
Source payment records
|
|||||
| Miro3D Normalized: miro3d |
Device | Reprise Biomedical, Inc. | $26.06 | 1 | 2025 |
Source payment records
|
|||||
| ZILVER PTX Normalized: zilver ptx |
Device | Cook Medical LLC | $23.29 | 2 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| General - Angioplasty Normalized: general angioplasty |
Device | Boston Scientific Corporation | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| ZENITH SPIRAL-Z Normalized: zenith spiral z |
Device | Cook Medical LLC | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| ZETUVIT PLUS 10X10 P10 Normalized: zetuvit plus 10x10 p10 |
Device | HARTMANN USA, INC. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 35 |
| Omeprazole | Omeprazole | 147 | 39 |
| Sucralfate | Sucralfate | 137 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 39 | 31 |
| Lubiprostone | Lubiprostone | 31 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Mupirocin | Mupirocin | 26 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | 21 |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | 19 |
| Levothyroxine Sodium | Levothyroxine Sodium | 17 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 12 |
| Amlodipine Besylate | Amlodipine Besylate | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Eliquis | Apixaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $35,034.80 · 59 records | INTUITIVE SURGICAL, INC. | AZURE XT DR MRI SURESCAN, COLLAGENASE SANTYL, DALVANCE, Da Vinci Surgical System, GRAFIX PL, General - Angioplasty, Integra, Integra Dermal Regeneration Template, LYMPHA PRESS OPTIMAL PLUS(US) BT, Miro3D, NUZYRA, PCD-51 731A (US) - White, PCD-52 737A (US) White, PERCLOSE PROSTYLE, PRIMATRIX, PURAPLY WOUND MATRIX, STRAVIX, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TheraGenesis Wound Matrix, VOQUEZNA, ZENITH SPIRAL-Z, ZETUVIT PLUS 10X10 P10, ZILVER PTX | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error